Skip to Main Content

Paper Details

PD-L1 quantification across tumor types using the reverse phase protein microarray: implications for precision medicine.
J Immunother Cancer
7
2021
22C3, 28-8, CAL10, E1L3N, PD-L1, SP142, anti-PD-L1 antibody, antibody clones, breast cancers, formalin, human, lung cancer, lung,, metastatic, ovarian,, paraffin, patients, programmed cell death ligand 1, programmed cell death protein 1, tumor, tumors
Author NameAffiliation
Lance A LiottaCenter for Applied Proteomics and Molecular Medicine, George Mason University
Johann S de BonoThe Institute of Cancer Research
Niven MehraThe Institute of Cancer Research
Giuseppe GiacconeLombardi Comprehensive Cancer Center, Georgetown University
Giuseppe GiacconeLombardi Comprehensive Cancer Center, Georgetown University
Emanuel F PetricoinCenter for Applied Proteomics and Molecular Medicine, George Mason University
Emanuel F PetricoinCenter for Applied Proteomics and Molecular Medicine, George Mason University
Mariaelena PierobonCenter for Applied Proteomics and Molecular Medicine, George Mason University
Mariaelena PierobonGeorge Mason University
  • 1 - 9

Datasets

Release 1.2